ERBB2 and breast cancer: Mutations in the phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha (PIK3CA) gene are highly prevalent (30–40%) in patients with HR+/HER2− advanced breast cancer [13–15].